Claudin 18.2: From a Tight Junction Protein to a Breakthrough Target in Solid Tumor Immunotherapy.
Zolbetuximab, a monoclonal antibody targeting a specific gastric cancer marker, improved survival in patients with advanced gastric cancer.
This phase 3 clinical trial examined Claudin 18;2: From a Tight Junction Protein to a Breakthrough Target in Solid Tumor Immunotherapy. The abstract reports that We discuss monoclonal antibodies, especially zolbetuximab, whose phase III SPOTLIGHT and GLOW trials improved survival in CLDN18;2-positive, HER2-negative gastric and gastroesophageal junction adenocarcinoma and led to regulatory approval.
What the study was
- Study design
- Phase 3 clinical trial
- Population
- Human participants
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Biomarkers
Why it surfaced
Phase 3 clinical trial; directly matches Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Conservative abstract-level score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.